The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

Drug manufacturers have increased their production, and some such as Novo Nordisk have asked the FDA to ban further production of compounded versions of their drugs. If that happens, Lavin says many ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

If you’ve noticed ads for weight loss injections flood your social media feeds, you’re not alone. The soaring popularity of ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

The company is anticipating significant benefits from the launch of tirzepatide in multiple countries outside the U.S., which suggests a potential increase in revenue streams. Furthermore, Eli Lilly’s ...

The Ipsos survey of 1,078 adults found 24 of people would use weight-loss jabs if they were provided for free by the health service.

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according to a study ...

The GLP-1 tirzepatide, the active ingredient in Eli Lilly's Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity, according to a study published Nov. 16 in The ...

Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly ...